Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 428-320-1 | CAS number: 71308-16-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- one-generation reproductive toxicity
- Remarks:
- based on test guideline (migrated information)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- July 2008 - Sept 2009
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Good quality GLP study conforming to applicable guidelines.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
- Report date:
- 2009
Materials and methods
Test guidelineopen allclose all
- Guideline:
- OECD Guideline 415 [One-Generation Reproduction Toxicity Study (before 9 October 2017)]
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.34 (One-Generation Reproduction Toxicity Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
Test animals
- Species:
- rat
- Strain:
- CD-1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: males 8-9 weeks, females 9-10 weeks
- Weight at study initiation: males 283.2-351.5 g, females205.5-258.4 g
- Fasting period before study: overnight
- Housing: The pre-mating animals and the pregnant females were kept singly, the rearing females together with their pups and the mating animals were kept as pairs
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C ± 3°C
- Humidity (%): 30-70%
- Photoperiod (hrs dark / hrs light): 12/12
In-life dates:
Males 1st Administration: July 28th 2008
Females 1st Administration: Sept 22nd 2008
Satellite Females 1st Administration: August 4th 2008
Termination of in-life phase: December 5th 2008
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- Oral, by gavage
Groups and Dose levels
Group 1 vehicle control
Group 2 31.6 mg/kg b.w./day
Group 3 100 mg/kg b.w./day
Group 4 316 mg/kg b.w./day - Details on mating procedure:
- Main Study Animals:
Sexually mature male and female rats (F0 generation) were randomly paired for mating.
Mating was monogamous: 1 male and 1 female animal were placed in one cage during the dark period. The female was placed with the same male until pregnancy occurred or three weeks had elapsed.
Each morning the females were examined for the presence of sperm or a vaginal plug. If findings were negative, mating was repeated. The day on which sperm or a vaginal plug was found was considered as the day of conception and was defined as day 0 of pregnancy. In case pairing was unsuccessful, re-mating of females with proven males of the same group were considered. This procedure was repeated until at least 20 pregnant dams were available for each main study group.
Satellite animals:
Four groups of pregnant satellite rats (8 animals per group) were formed from monogamous matings with non-study sires of the same strain which were carried out on a daily basis. The satellite females were assigned to their respective groups according to their mating day i.e. in a cyclic way following the listing of positive findings during vaginal lavages (taken each morning and the stages of oestrus cycle were recorded). - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Test item-vehicle solution samples were taken by LPT during the course of the study. The samples were stored at -20 °C and were analysed by LPT.
- Duration of treatment / exposure:
- 5 mL/kg b.w./day administered once daily, 7 days per week
- Frequency of treatment:
- Once daily, 7 days per week
- No. of animals per sex per dose:
- 192 F0 animals (96 male and 96 female animals)
i.e. 24 males and 24 females per group in order to obtain at least 20 pregnant females per group for evaluation of the F0 generation.
Teratogenic effects (Satellite animals)
10 female animals were allocated to groups 1 to 4 for screening for teratogenic effects, a sufficient number to obtain at least 8 pregnant animals for each group. - Control animals:
- yes, concurrent vehicle
Examinations
- Parental animals: Observations and examinations:
- Mortality: One high dosed female rat treated with 316 mg prematurely during parturition on test day 99.
Clinical signs
Treatment with 100 or 316 mg/kg b.w./day led to haemorrhagic urine in 4 of 24 (group 3) or 13 of 24 (group 4) male rats during pre-mating and mating, starting on test days 68 or 16 during the pre-mating period, respectively.
Haemorrhagic urine was not noted in any of the dosed female rats.
Further, treatment with 316 mg/kg b.w./day led to salivation (slight or moderate) in a few male rats during pre-mating and mating on up to 11 test days as well as in 1 or 2 females during pre-mating, mating and gestation, starting on test day 26 (males) or on test day 66 (females) during the pre-mating period.
Body weight and body weight gain:
Males
The mean body weight of the males animals treated with 100 mg/kg b.w./day was slightly but significantly decreased by 7% from test week 2 onwards until the end of the mating period (by 9% in test week 13).
Treatment with 316 mg/kg b.w./day led to a markedly significantly decreased mean body weight from pre-mating week 1 onwards until the end of the mating period in test week 13 (by 11% in test week 1, by 20% in test week 13).
Body weight gain was reduced accordingly in both groups.
Females
The mean body weight of the females treated with 100 mg/kg b.w./day of test substance was slightly decreased during the pre-mating period (by 4%), during the mating period (by 6%) and slightly reduced during the entire gestation period (up to 6%).
Treatment with 316 mg/kg b.w./day led to a reduced mean body weight of the female animals from test week 1 onwards (by up to 18%) until the end of the lactation period (statistically significant at p ≤ 0.01 during pre-mating, mating and gestation, as well as on lactation days 4 and 7). Body weight gain was reduced accordingly in both groups.
Food consumption
Males
The male rats treated with 100 or 316 mg/kg b.w./day of the test susbtance revealed a significantly decreased food intake in test week 1 of the pre-mating period (by 11% and by 19%, respectively).
Females
The females treated with 100 or 316 mg/kg b.w./day revealed a significantly decreased food intake by 11% (group 3) and by 23% (group 4) in test week 1 of the pre-mating period.
Treatment with 316 mg/kg b.w./day revealed a significantly reduced mean relative food intake on lactation days 4 to 21 (up to 37% on lactation day 14).
Drinking water consumption:
No test item-related influence was noted. - Oestrous cyclicity (parental animals):
- No test item-related influence was noted on the total number, length or number of abnormal cycles of the oestrous cycles.
A slightly reduced female fertility index was noted in the high dose group after treatment with 316 mg/kg b.w./day. - Sperm parameters (parental animals):
- Treatment with 316 mg/kg b.w./day led to a slightly reduced mean percentage of motile spermatozoa in the male rats (by 61.40%, statistically not significant, control: 69.61%).
Further, the mean percentage of morphologically normal spermatids was slightly reduced in the high dosed male rats at 316 mg/kg b.w./day (statistically not significant).
No test item-related influence was noted on the male fertility at any of the tested dose levels. - Litter observations:
- Treatment with 316 mg/kg b.w./day led to a slightly reduced mean body weight of male and female pups from lactation day 1 onwards until lactation day 7 (by 15% in males, by 15% or 16% in females).
No test item-related influence was noted on the physical development of the F1 pups at any of the tested dose levels. - Postmortem examinations (parental animals):
- Macroscopic:
Treatment with 316 mg/kg b.w./day led to macroscopic changes in form of an enlarged spleen in all 20 high dosed male rats and in four female animals. The spleen of one further female animal was partly adhered to fatty tissue.
Microscopic:
The histomorphological examination revealed morphological lesions in the spleen of group 4 animals which are considered to be related to the test item. Microscopic changes of the spleen in form of congestion, brownish pigments and haematopoiesis were noted in 15 male and 4 female high-dosed animals. Spermatic granuloma were noted in the epididymis of 3 of 20 male test item-treated males of the high dose. - Postmortem examinations (offspring):
- Macroscopic inspection at necropsy did not reveal any test item-related changes in the organs or tissues of the F1 pups.
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- -Haemorrhagic urine in 4 of 24 (group 3) or 13 of 24 (group 4) male rats during pre-mating and mating.Haemorrhagic urine was not noted in any of the dosed female rats. -Salivation (slight or moderate) noticed in some animals.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Slight decrease m/f
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Slight decrease m/f
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Spleen lesions in all highest dose anmials. Spermatic granuloma in 3 of 20 males in highest-dose group.
- Other effects:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- effects observed, treatment-related
- Description (incidence and severity):
- At highest dose, slightly reduced mean percentage of motile spermatozoa in the male rats.
- Reproductive performance:
- effects observed, treatment-related
- Description (incidence and severity):
- The mean number of viable male and female pups at birth was statistical significantly decreased in the high dose group (316 mg/kg bw/day.
Details on results (P0)
Effect levels (P0)
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- > 31.6 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Effects on the parental F0 Generation
- Dose descriptor:
- NOEL
- Effect level:
- > 31.6 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Screening for Teratogenic Effects (Satellite Animals): Effects on the dams
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- High-dose group (316 mg/kg bw/day): Slightly reduced mean body weight of male and female pups from lactation day 1 onwards until lactation day 7.
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
Effect levels (F1)
open allclose all
- Dose descriptor:
- NOEL
- Generation:
- F1
- Effect level:
- > 31.6 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Effects on the development of the conceptus and the offspring (F1 generation) through sexual maturity
- Dose descriptor:
- NOEL
- Generation:
- F1
- Effect level:
- > 100 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Screening for Teratogenic Effects (Satellite Animals): Effects on the Fetuses.
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- One-generation Reproductive Toxicity Study:
Under the test conditions the following NOELs were noted after administration by oral gavage during pre-mating and mating periods (parental males) and during the pre-mating, mating, gestation and lactation periods (parental females):
Effects on the parental F0 Generation:
NOEL 31.6 mg/kg bw/day
Effects on the development of the conceptus and the offspring (F1 generation) through sexual maturity:
NOEL 31.6 mg/kg bw/day
Screening for Teratogenic Effects (Satellite Animals)
Under the test conditions the following NOELs were noted following adminstration by oral gavage from the 6th to 19th days of pregnancy:
Effects on the dams:
NOEL 31.6 mg/kg bw/day
Effects on the Fetuses:
NOEL 100 mg/kg bw/day
No teratogenic properties were noted even at materno-toxic dose levels up to 316mg/kg/day
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.